This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Firmenich-DSM secures last merger clearance following Indian approval

By Freny Patel ( April 3, 2023, 23:15 GMT | Insight) -- Swiss perfume and flavors company Firmenich and Dutch-Swiss health, nutrition and bioscience company Koninklijke DSM have cleared the last hurdle in their planned merger, with India’s competition regulator announcing on Monday that it wouldn’t oppose the deal. The Competition Commission of India approved the transaction after the parties refiled under Form II, when their initial application under Form III was considered “not valid.” Shareholders have two weeks before the acceptance period closes to tender their shares, starting tomorrow and running until April 17.Swiss perfume and flavors company Firmenich and Dutch-Swiss health, nutrition and bioscience company Koninklijke DSM have cleared the last hurdle in their planned merger, with India’s competition regulator announcing on Monday that it wouldn’t oppose the deal....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login